At the 70th annual meeting of the American Epilepsy Society in Houston this week, GW Pharmaceuticals announced results of the first ever randomized, double-blind, placebo-controlled studies of CBD. The company’s proprietary CBD drug is called Epidiolex.
In the Dravet syndrome study, 43 percent of patients taking Epidiolex had a greater than or equal to 50 percent reduction in convulsive seizures compared to 27 percent of patients taking placebo. Seven patients taking Epidiolex achieved total seizure freedom. Click here to see data.
In the Lennox Gastaut syndrome study, 44.2 percent of Epidiolex patients had a greater than or equal to 50 percent reduction in drop seizures compared to 23.5 percent of patients taking placebo. Click here to see data.
“These placebo-controlled studies demonstrate that Epidiolex provides clinically meaningful reductions in seizure frequency together with an acceptable safety and tolerability profile,” stated Orrin Devinsky, MD, of New York University Langone Medical Center’s Comprehensive Epilepsy Center and Principal Investigator of the Dravet syndrome trial. “My colleagues and I are excited at the future prospect of prescribing an appropriately standardized and tested pharmaceutical formulation of cannabidiol.”
Posters presenting the data note that findings reported in these studies are specific to GW Pharmaceuticals’ formulation of cannabidiol and cannot be extrapolated to other CBD products.
As the chart above illustrates, having completed clinical trials with more than 1,500 patients, including expanded access trials for more than 1,000, GW plans to seek a New Drug Application (NDA) for FDA approval in a few months. If approved, GW will market Epidiolex under a new company name in the US: Greenwich Biosciences.
Featured Website
World Federation Against Drugs
World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
Featured Website
Institute for Behavior and Health
The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Featured Website
Drug Free Australia
Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
Featured Website
Drug Advisory Council of Australia (D.A.C.A)
Drug Advisory Council of Australia (D.A.C.A) Dalgarno Institute is an executive member of this peak body. For updates on current illicit drug issues.
Featured Website
International Task Force on Strategic Drug Policy
(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
Featured Website
Smart Approaches to Marijuana
Smart Approaches to Marijuana. SAM's leaders are among the world's most prominent voices calling for science-based marijuana education and awareness.
21 Be There
There isn’t merely data sharing - it isn't about promoting a 'one dimensional' legislative solution to a complex problem
Featured Website
Drug Free Futures
Drug Policy Futures believes in engaging in an open dialogue about the strengths and weaknesses of global drug policies...
Featured Website
Action Alcohol
The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
Featured Website
Rivermend Health
RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
Featured Website
Evidence-Based Practices Resource Center
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
Featured Website
SAMHSA
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.